The company said this morning that the COAST trial of sozinibercept (OPT-302) as a combination therapy with blockbuster wet AMD therapy Regeneron ... sozinibercept, a VEGF 'trap' compound that ...

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to broaden its capacity. Valued at more than $3bn, the partnership is set to ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

$3 billion FUJIFILM deal will nearly double Regeneron’s large-scale U.S. biologics manufacturing capacity over the next decade. Regeneron adds 7,000+ U.S. jobs in five years, with $7B+ in ...

April 22 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to help manufacture its medicines in the US, as the threat of tariffs looms ...

Under a new 10-year agreement, Regeneron will pay CDMO powerhouse Fujifilm Diosynth Biotechnologies more than $3 billion to help manufacture bulk drug product for its commercial biologics in the ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs ...

Regeneron announced a major expansion of its biologics manufacturing capabilities through a new partnership with FUJIFILM Diosynth Biotechnologies. According to the company, the deal will nearly ...

The indication is key as Sanofi and U.S. partner Regeneron expect sales of Dupixent to reach $22 billion by 2030. Sanofi off to a promising start in launch of Dupixent for COPD Fierce Pharma ...

FUJIFILM Diosynth Biotechnologies signed a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines.